nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemcitabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—skin cancer	0.651	1	CiPCiCtD
Gemcitabine—SLC29A1—Fluorouracil—skin cancer	0.0686	0.348	CbGbCtD
Gemcitabine—TYMS—Fluorouracil—skin cancer	0.0636	0.323	CbGbCtD
Gemcitabine—ABCC10—Docetaxel—skin cancer	0.04	0.203	CbGbCtD
Gemcitabine—ABCB1—Vismodegib—skin cancer	0.0138	0.0698	CbGbCtD
Gemcitabine—ABCB1—Dactinomycin—skin cancer	0.00723	0.0367	CbGbCtD
Gemcitabine—ABCB1—Docetaxel—skin cancer	0.00373	0.0189	CbGbCtD
Gemcitabine—POLD1—Mismatch repair—MSH2—skin cancer	0.00171	0.0405	CbGpPWpGaD
Gemcitabine—POLD1—Global Genomic NER (GG-NER)—XPA—skin cancer	0.00167	0.0396	CbGpPWpGaD
Gemcitabine—POLE—Global Genomic NER (GG-NER)—XPA—skin cancer	0.00162	0.0383	CbGpPWpGaD
Gemcitabine—POLD1—Mismatch repair—MLH1—skin cancer	0.00154	0.0365	CbGpPWpGaD
Gemcitabine—CDA—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00151	0.0359	CbGpPWpGaD
Gemcitabine—CMPK1—hair follicle—skin cancer	0.00148	0.0485	CbGeAlD
Gemcitabine—POLD1—neck—skin cancer	0.00124	0.0408	CbGeAlD
Gemcitabine—POLD1—Nucleotide Excision Repair—XPA—skin cancer	0.00123	0.0291	CbGpPWpGaD
Gemcitabine—POLE—Nucleotide Excision Repair—XPA—skin cancer	0.00119	0.0281	CbGpPWpGaD
Gemcitabine—SLC28A3—nipple—skin cancer	0.00115	0.0378	CbGeAlD
Gemcitabine—RRM1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00115	0.0272	CbGpPWpGaD
Gemcitabine—POLD1—Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)—MSH2—skin cancer	0.00114	0.0269	CbGpPWpGaD
Gemcitabine—POLD1—Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)—MSH2—skin cancer	0.00114	0.0269	CbGpPWpGaD
Gemcitabine—POLD1—MMR—MSH2—skin cancer	0.00108	0.0256	CbGpPWpGaD
Gemcitabine—POLD1—Base Excision Repair—XRCC1—skin cancer	0.00106	0.0251	CbGpPWpGaD
Gemcitabine—SLC29A1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00105	0.0249	CbGpPWpGaD
Gemcitabine—POLD1—Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)—MLH1—skin cancer	0.00102	0.0243	CbGpPWpGaD
Gemcitabine—POLD1—Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)—MLH1—skin cancer	0.00102	0.0243	CbGpPWpGaD
Gemcitabine—POLD1—MMR—MLH1—skin cancer	0.000973	0.0231	CbGpPWpGaD
Gemcitabine—RRM2—Sorafenib—Vismodegib—skin cancer	0.000949	0.577	CbGdCrCtD
Gemcitabine—RRM1—hair follicle—skin cancer	0.000947	0.0311	CbGeAlD
Gemcitabine—RRM2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000944	0.0224	CbGpPWpGaD
Gemcitabine—POLE—nipple—skin cancer	0.000939	0.0308	CbGeAlD
Gemcitabine—POLD1—DNA Repair—POLH—skin cancer	0.000844	0.02	CbGpPWpGaD
Gemcitabine—POLE—DNA Repair—POLH—skin cancer	0.000815	0.0193	CbGpPWpGaD
Gemcitabine—POLD1—skin of body—skin cancer	0.000804	0.0264	CbGeAlD
Gemcitabine—CMPK1—connective tissue—skin cancer	0.000711	0.0233	CbGeAlD
Gemcitabine—POLD1—Cytosolic iron-sulfur cluster assembly—ERCC2—skin cancer	0.000696	0.0165	CbGpPWpGaD
Gemcitabine—SLC28A3—mammalian vulva—skin cancer	0.000673	0.0221	CbGeAlD
Gemcitabine—CDA—mammalian vulva—skin cancer	0.000658	0.0216	CbGeAlD
Gemcitabine—POLD1—lymphoid tissue—skin cancer	0.000651	0.0214	CbGeAlD
Gemcitabine—RRM1—nipple—skin cancer	0.000642	0.0211	CbGeAlD
Gemcitabine—CMPK1—skin of body—skin cancer	0.000642	0.0211	CbGeAlD
Gemcitabine—POLD1—DNA Repair—XPA—skin cancer	0.00064	0.0152	CbGpPWpGaD
Gemcitabine—POLD1—female reproductive system—skin cancer	0.000628	0.0206	CbGeAlD
Gemcitabine—TYMS—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000619	0.0147	CbGpPWpGaD
Gemcitabine—POLE—DNA Repair—XPA—skin cancer	0.000618	0.0146	CbGpPWpGaD
Gemcitabine—CDA—lymphoid tissue—skin cancer	0.000584	0.0192	CbGeAlD
Gemcitabine—POLE—mammalian vulva—skin cancer	0.000548	0.018	CbGeAlD
Gemcitabine—CDA—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000532	0.0126	CbGpPWpGaD
Gemcitabine—SLC29A2—female reproductive system—skin cancer	0.000527	0.0173	CbGeAlD
Gemcitabine—POLD1—head—skin cancer	0.000525	0.0172	CbGeAlD
Gemcitabine—SLC29A1—nipple—skin cancer	0.000522	0.0171	CbGeAlD
Gemcitabine—CMPK1—lymphoid tissue—skin cancer	0.00052	0.0171	CbGeAlD
Gemcitabine—CMPK1—female reproductive system—skin cancer	0.000501	0.0164	CbGeAlD
Gemcitabine—DCK—nipple—skin cancer	0.000499	0.0164	CbGeAlD
Gemcitabine—RRM2—skin of body—skin cancer	0.000495	0.0163	CbGeAlD
Gemcitabine—POLE—lymphoid tissue—skin cancer	0.000487	0.016	CbGeAlD
Gemcitabine—ABCC10—nipple—skin cancer	0.000475	0.0156	CbGeAlD
Gemcitabine—POLA1—mammalian vulva—skin cancer	0.000473	0.0155	CbGeAlD
Gemcitabine—POLE—female reproductive system—skin cancer	0.00047	0.0154	CbGeAlD
Gemcitabine—RRM2—mammalian vulva—skin cancer	0.000452	0.0148	CbGeAlD
Gemcitabine—RRM1—E2F transcription factor network—XRCC1—skin cancer	0.000441	0.0105	CbGpPWpGaD
Gemcitabine—CMPK1—head—skin cancer	0.000419	0.0137	CbGeAlD
Gemcitabine—TYMS—connective tissue—skin cancer	0.000413	0.0136	CbGeAlD
Gemcitabine—RRM1—skin of body—skin cancer	0.000411	0.0135	CbGeAlD
Gemcitabine—TYMS—Sorafenib—Vismodegib—skin cancer	0.000405	0.247	CbGdCrCtD
Gemcitabine—RRM1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000403	0.00956	CbGpPWpGaD
Gemcitabine—RRM2—lymphoid tissue—skin cancer	0.000401	0.0132	CbGeAlD
Gemcitabine—POLE—head—skin cancer	0.000392	0.0129	CbGeAlD
Gemcitabine—RRM2—female reproductive system—skin cancer	0.000387	0.0127	CbGeAlD
Gemcitabine—RRM1—mammalian vulva—skin cancer	0.000375	0.0123	CbGeAlD
Gemcitabine—SLC28A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000373	0.00884	CbGpPWpGaD
Gemcitabine—TYMS—skin of body—skin cancer	0.000373	0.0122	CbGeAlD
Gemcitabine—SLC29A1—connective tissue—skin cancer	0.00037	0.0122	CbGeAlD
Gemcitabine—SLC29A1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000369	0.00875	CbGpPWpGaD
Gemcitabine—POLD1—lymph node—skin cancer	0.000367	0.0121	CbGeAlD
Gemcitabine—RRM2—E2F transcription factor network—XRCC1—skin cancer	0.000363	0.00861	CbGpPWpGaD
Gemcitabine—POLD1—Extension of Telomeres—TERT—skin cancer	0.000343	0.00814	CbGpPWpGaD
Gemcitabine—TYMS—mammalian vulva—skin cancer	0.00034	0.0112	CbGeAlD
Gemcitabine—RRM1—lymphoid tissue—skin cancer	0.000333	0.0109	CbGeAlD
Gemcitabine—RRM2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000332	0.00787	CbGpPWpGaD
Gemcitabine—POLE—Extension of Telomeres—TERT—skin cancer	0.000332	0.00786	CbGpPWpGaD
Gemcitabine—CDA—lymph node—skin cancer	0.00033	0.0108	CbGeAlD
Gemcitabine—RRM2—head—skin cancer	0.000323	0.0106	CbGeAlD
Gemcitabine—POLD1—Global Genomic NER (GG-NER)—ERCC2—skin cancer	0.000322	0.00764	CbGpPWpGaD
Gemcitabine—RRM1—female reproductive system—skin cancer	0.000321	0.0105	CbGeAlD
Gemcitabine—POLE—Global Genomic NER (GG-NER)—ERCC2—skin cancer	0.000311	0.00738	CbGpPWpGaD
Gemcitabine—SLC29A2—lymph node—skin cancer	0.000308	0.0101	CbGeAlD
Gemcitabine—SLC29A1—mammalian vulva—skin cancer	0.000305	0.01	CbGeAlD
Gemcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000304	0.00721	CbGpPWpGaD
Gemcitabine—TYMS—lymphoid tissue—skin cancer	0.000302	0.00991	CbGeAlD
Gemcitabine—CMPK1—lymph node—skin cancer	0.000293	0.00962	CbGeAlD
Gemcitabine—DCK—mammalian vulva—skin cancer	0.000291	0.00956	CbGeAlD
Gemcitabine—TYMS—female reproductive system—skin cancer	0.000291	0.00956	CbGeAlD
Gemcitabine—TYMS—Paclitaxel—Docetaxel—skin cancer	0.000289	0.176	CbGdCrCtD
Gemcitabine—SLC28A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000283	0.0067	CbGpPWpGaD
Gemcitabine—ABCC10—mammalian vulva—skin cancer	0.000278	0.00911	CbGeAlD
Gemcitabine—POLE—lymph node—skin cancer	0.000275	0.00902	CbGeAlD
Gemcitabine—SLC29A1—lymphoid tissue—skin cancer	0.000271	0.00889	CbGeAlD
Gemcitabine—RRM1—head—skin cancer	0.000268	0.00881	CbGeAlD
Gemcitabine—SLC29A1—female reproductive system—skin cancer	0.000261	0.00857	CbGeAlD
Gemcitabine—DCK—lymphoid tissue—skin cancer	0.000259	0.00849	CbGeAlD
Gemcitabine—POLD1—Transcription-coupled NER (TC-NER)—ERCC2—skin cancer	0.000258	0.00611	CbGpPWpGaD
Gemcitabine—POLD1—DNA Repair—XRCC1—skin cancer	0.000255	0.00604	CbGpPWpGaD
Gemcitabine—DCK—female reproductive system—skin cancer	0.00025	0.00819	CbGeAlD
Gemcitabine—POLE—Transcription-coupled NER (TC-NER)—ERCC2—skin cancer	0.000249	0.0059	CbGpPWpGaD
Gemcitabine—POLA1—E2F transcription factor network—XRCC1—skin cancer	0.000249	0.00589	CbGpPWpGaD
Gemcitabine—ABCC10—lymphoid tissue—skin cancer	0.000246	0.00809	CbGeAlD
Gemcitabine—POLE—DNA Repair—XRCC1—skin cancer	0.000246	0.00583	CbGpPWpGaD
Gemcitabine—TYMS—head—skin cancer	0.000243	0.00799	CbGeAlD
Gemcitabine—TYMS—E2F transcription factor network—XRCC1—skin cancer	0.000238	0.00564	CbGpPWpGaD
Gemcitabine—ABCC10—female reproductive system—skin cancer	0.000238	0.0078	CbGeAlD
Gemcitabine—POLD1—Nucleotide Excision Repair—ERCC2—skin cancer	0.000237	0.00561	CbGpPWpGaD
Gemcitabine—POLA1—lymph node—skin cancer	0.000237	0.00777	CbGeAlD
Gemcitabine—POLA1—Extension of Telomeres—TERT—skin cancer	0.000236	0.0056	CbGpPWpGaD
Gemcitabine—POLE—Nucleotide Excision Repair—ERCC2—skin cancer	0.000229	0.00542	CbGpPWpGaD
Gemcitabine—RRM2—lymph node—skin cancer	0.000226	0.00743	CbGeAlD
Gemcitabine—POLD1—DNA Repair—MSH2—skin cancer	0.000226	0.00535	CbGpPWpGaD
Gemcitabine—SLC29A1—head—skin cancer	0.000218	0.00716	CbGeAlD
Gemcitabine—POLE—DNA Repair—MSH2—skin cancer	0.000218	0.00517	CbGpPWpGaD
Gemcitabine—TYMS—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000218	0.00516	CbGpPWpGaD
Gemcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000211	0.005	CbGpPWpGaD
Gemcitabine—DCK—head—skin cancer	0.000208	0.00684	CbGeAlD
Gemcitabine—POLD1—DNA Repair—MLH1—skin cancer	0.000204	0.00483	CbGpPWpGaD
Gemcitabine—POLE—DNA Repair—MLH1—skin cancer	0.000197	0.00466	CbGpPWpGaD
Gemcitabine—CDA—Fluoropyrimidine Activity—TP53—skin cancer	0.00019	0.0045	CbGpPWpGaD
Gemcitabine—ABCB1—blood vessel—skin cancer	0.00019	0.00623	CbGeAlD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00019	0.00449	CbGpPWpGaD
Gemcitabine—RRM1—lymph node—skin cancer	0.000188	0.00617	CbGeAlD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000171	0.00404	CbGpPWpGaD
Gemcitabine—TYMS—lymph node—skin cancer	0.00017	0.00559	CbGeAlD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000162	0.00383	CbGpPWpGaD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000156	0.00369	CbGpPWpGaD
Gemcitabine—POLD1—Telomere Maintenance—TERT—skin cancer	0.000156	0.00369	CbGpPWpGaD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000155	0.00366	CbGpPWpGaD
Gemcitabine—TYMS—Circadian rythm related genes—NKX2-1—skin cancer	0.000153	0.00362	CbGpPWpGaD
Gemcitabine—SLC29A1—lymph node—skin cancer	0.000153	0.00502	CbGeAlD
Gemcitabine—POLE—Telomere Maintenance—TERT—skin cancer	0.00015	0.00356	CbGpPWpGaD
Gemcitabine—POLE—G1 to S cell cycle control—CDK4—skin cancer	0.00015	0.00356	CbGpPWpGaD
Gemcitabine—DCK—lymph node—skin cancer	0.000146	0.00479	CbGeAlD
Gemcitabine—RRM1—Fluoropyrimidine Activity—TP53—skin cancer	0.000144	0.00341	CbGpPWpGaD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000144	0.00341	CbGpPWpGaD
Gemcitabine—ABCC10—lymph node—skin cancer	0.000139	0.00457	CbGeAlD
Gemcitabine—RRM1—E2F transcription factor network—CDKN2A—skin cancer	0.000137	0.00325	CbGpPWpGaD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000135	0.0032	CbGpPWpGaD
Gemcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—skin cancer	0.000132	0.00312	CbGpPWpGaD
Gemcitabine—POLD1—Chromosome Maintenance—TERT—skin cancer	0.00013	0.00307	CbGpPWpGaD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000128	0.00304	CbGpPWpGaD
Gemcitabine—POLE—Chromosome Maintenance—TERT—skin cancer	0.000125	0.00297	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—PLIN2—skin cancer	0.000124	0.00293	CbGpPWpGaD
Gemcitabine—POLD1—DNA Repair—ERCC2—skin cancer	0.000123	0.00292	CbGpPWpGaD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000123	0.00292	CbGpPWpGaD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000121	0.00287	CbGpPWpGaD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.00012	0.00284	CbGpPWpGaD
Gemcitabine—POLE—DNA Repair—ERCC2—skin cancer	0.000119	0.00282	CbGpPWpGaD
Gemcitabine—RRM2—Fluoropyrimidine Activity—TP53—skin cancer	0.000119	0.00281	CbGpPWpGaD
Gemcitabine—POLE—G1 to S cell cycle control—CDKN2A—skin cancer	0.000115	0.00272	CbGpPWpGaD
Gemcitabine—RRM2—E2F transcription factor network—CDKN2A—skin cancer	0.000113	0.00268	CbGpPWpGaD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000107	0.00254	CbGpPWpGaD
Gemcitabine—POLA1—Telomere Maintenance—TERT—skin cancer	0.000107	0.00254	CbGpPWpGaD
Gemcitabine—Chills—Bleomycin—skin cancer	9.99e-05	0.00129	CcSEcCtD
Gemcitabine—CMPK1—Metabolism—CSPG4—skin cancer	9.96e-05	0.00236	CbGpPWpGaD
Gemcitabine—Cardiac failure congestive—Docetaxel—skin cancer	9.95e-05	0.00128	CcSEcCtD
Gemcitabine—Dyspnoea—Imiquimod—skin cancer	9.93e-05	0.00128	CcSEcCtD
Gemcitabine—Somnolence—Imiquimod—skin cancer	9.9e-05	0.00128	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Temozolomide—skin cancer	9.89e-05	0.00128	CcSEcCtD
Gemcitabine—Alopecia—Bleomycin—skin cancer	9.84e-05	0.00127	CcSEcCtD
Gemcitabine—Erythema multiforme—Dactinomycin—skin cancer	9.82e-05	0.00127	CcSEcCtD
Gemcitabine—Pneumonia—Fluorouracil—skin cancer	9.7e-05	0.00125	CcSEcCtD
Gemcitabine—Erythema—Bleomycin—skin cancer	9.69e-05	0.00125	CcSEcCtD
Gemcitabine—Decreased appetite—Imiquimod—skin cancer	9.68e-05	0.00125	CcSEcCtD
Gemcitabine—POLD1—S Phase—CDK4—skin cancer	9.67e-05	0.00229	CbGpPWpGaD
Gemcitabine—Gastrointestinal disorder—Imiquimod—skin cancer	9.61e-05	0.00124	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	9.6e-05	0.00228	CbGpPWpGaD
Gemcitabine—Fatigue—Imiquimod—skin cancer	9.6e-05	0.00124	CcSEcCtD
Gemcitabine—Pain—Imiquimod—skin cancer	9.52e-05	0.00123	CcSEcCtD
Gemcitabine—Acute coronary syndrome—Fluorouracil—skin cancer	9.5e-05	0.00123	CcSEcCtD
Gemcitabine—Renal impairment—Docetaxel—skin cancer	9.49e-05	0.00122	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Fluorouracil—skin cancer	9.45e-05	0.00122	CcSEcCtD
Gemcitabine—Myocardial infarction—Fluorouracil—skin cancer	9.45e-05	0.00122	CcSEcCtD
Gemcitabine—Dermatitis bullous—Docetaxel—skin cancer	9.45e-05	0.00122	CcSEcCtD
Gemcitabine—Haemoglobin—Temozolomide—skin cancer	9.44e-05	0.00122	CcSEcCtD
Gemcitabine—Stomatitis—Fluorouracil—skin cancer	9.4e-05	0.00121	CcSEcCtD
Gemcitabine—Haemorrhage—Temozolomide—skin cancer	9.39e-05	0.00121	CcSEcCtD
Gemcitabine—Asthenia—Vemurafenib—skin cancer	9.37e-05	0.00121	CcSEcCtD
Gemcitabine—POLE—S Phase—CDK4—skin cancer	9.34e-05	0.00221	CbGpPWpGaD
Gemcitabine—Pharyngitis—Temozolomide—skin cancer	9.32e-05	0.0012	CcSEcCtD
Gemcitabine—Chills—Dactinomycin—skin cancer	9.32e-05	0.0012	CcSEcCtD
Gemcitabine—Urinary tract disorder—Temozolomide—skin cancer	9.27e-05	0.0012	CcSEcCtD
Gemcitabine—Oedema peripheral—Temozolomide—skin cancer	9.25e-05	0.00119	CcSEcCtD
Gemcitabine—Cardiac failure—Docetaxel—skin cancer	9.25e-05	0.00119	CcSEcCtD
Gemcitabine—ABCB1—epithelium—skin cancer	9.24e-05	0.00303	CbGeAlD
Gemcitabine—Pruritus—Vemurafenib—skin cancer	9.24e-05	0.00119	CcSEcCtD
Gemcitabine—Connective tissue disorder—Temozolomide—skin cancer	9.23e-05	0.00119	CcSEcCtD
Gemcitabine—Urethral disorder—Temozolomide—skin cancer	9.21e-05	0.00119	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	9.2e-05	0.00218	CbGpPWpGaD
Gemcitabine—Alopecia—Dactinomycin—skin cancer	9.18e-05	0.00118	CcSEcCtD
Gemcitabine—Feeling abnormal—Imiquimod—skin cancer	9.17e-05	0.00118	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	9.1e-05	0.00216	CbGpPWpGaD
Gemcitabine—Erythema—Dactinomycin—skin cancer	9.04e-05	0.00117	CcSEcCtD
Gemcitabine—RRM2—Mitotic G1-G1/S phases—CDK4—skin cancer	9.03e-05	0.00214	CbGpPWpGaD
Gemcitabine—Agranulocytosis—Fluorouracil—skin cancer	9e-05	0.00116	CcSEcCtD
Gemcitabine—Ill-defined disorder—Bleomycin—skin cancer	8.99e-05	0.00116	CcSEcCtD
Gemcitabine—Anaemia—Bleomycin—skin cancer	8.96e-05	0.00116	CcSEcCtD
Gemcitabine—Diarrhoea—Vemurafenib—skin cancer	8.93e-05	0.00115	CcSEcCtD
Gemcitabine—POLA1—Chromosome Maintenance—TERT—skin cancer	8.92e-05	0.00211	CbGpPWpGaD
Gemcitabine—Erythema multiforme—Temozolomide—skin cancer	8.88e-05	0.00115	CcSEcCtD
Gemcitabine—Body temperature increased—Imiquimod—skin cancer	8.8e-05	0.00114	CcSEcCtD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	8.78e-05	0.00208	CbGpPWpGaD
Gemcitabine—Malaise—Bleomycin—skin cancer	8.74e-05	0.00113	CcSEcCtD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	8.72e-05	0.00207	CbGpPWpGaD
Gemcitabine—Cardiac disorder—Temozolomide—skin cancer	8.72e-05	0.00112	CcSEcCtD
Gemcitabine—Haemoglobin—Fluorouracil—skin cancer	8.7e-05	0.00112	CcSEcCtD
Gemcitabine—Leukopenia—Bleomycin—skin cancer	8.68e-05	0.00112	CcSEcCtD
Gemcitabine—Rhinitis—Fluorouracil—skin cancer	8.67e-05	0.00112	CcSEcCtD
Gemcitabine—POLE—Mitotic G1-G1/S phases—CDK4—skin cancer	8.67e-05	0.00205	CbGpPWpGaD
Gemcitabine—Haemorrhage—Fluorouracil—skin cancer	8.65e-05	0.00112	CcSEcCtD
Gemcitabine—Pharyngitis—Fluorouracil—skin cancer	8.59e-05	0.00111	CcSEcCtD
Gemcitabine—Angiopathy—Temozolomide—skin cancer	8.52e-05	0.0011	CcSEcCtD
Gemcitabine—Immune system disorder—Temozolomide—skin cancer	8.48e-05	0.00109	CcSEcCtD
Gemcitabine—Mediastinal disorder—Temozolomide—skin cancer	8.46e-05	0.00109	CcSEcCtD
Gemcitabine—Cough—Bleomycin—skin cancer	8.46e-05	0.00109	CcSEcCtD
Gemcitabine—Chills—Temozolomide—skin cancer	8.43e-05	0.00109	CcSEcCtD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	8.41e-05	0.00199	CbGpPWpGaD
Gemcitabine—Ill-defined disorder—Dactinomycin—skin cancer	8.39e-05	0.00108	CcSEcCtD
Gemcitabine—Anaemia—Dactinomycin—skin cancer	8.35e-05	0.00108	CcSEcCtD
Gemcitabine—Liver function test abnormal—Docetaxel—skin cancer	8.33e-05	0.00108	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	8.31e-05	0.00197	CbGpPWpGaD
Gemcitabine—Vomiting—Vemurafenib—skin cancer	8.3e-05	0.00107	CcSEcCtD
Gemcitabine—Alopecia—Temozolomide—skin cancer	8.3e-05	0.00107	CcSEcCtD
Gemcitabine—Chest pain—Bleomycin—skin cancer	8.25e-05	0.00106	CcSEcCtD
Gemcitabine—Myalgia—Bleomycin—skin cancer	8.25e-05	0.00106	CcSEcCtD
Gemcitabine—Rash—Vemurafenib—skin cancer	8.23e-05	0.00106	CcSEcCtD
Gemcitabine—Dermatitis—Vemurafenib—skin cancer	8.22e-05	0.00106	CcSEcCtD
Gemcitabine—Headache—Vemurafenib—skin cancer	8.18e-05	0.00106	CcSEcCtD
Gemcitabine—Erythema—Temozolomide—skin cancer	8.18e-05	0.00105	CcSEcCtD
Gemcitabine—Discomfort—Bleomycin—skin cancer	8.15e-05	0.00105	CcSEcCtD
Gemcitabine—Malaise—Dactinomycin—skin cancer	8.15e-05	0.00105	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Docetaxel—skin cancer	8.13e-05	0.00105	CcSEcCtD
Gemcitabine—Aspartate aminotransferase increased—Docetaxel—skin cancer	8.13e-05	0.00105	CcSEcCtD
Gemcitabine—Leukopenia—Dactinomycin—skin cancer	8.09e-05	0.00104	CcSEcCtD
Gemcitabine—ABCB1—mammalian vulva—skin cancer	8.02e-05	0.00263	CbGeAlD
Gemcitabine—Asthenia—Imiquimod—skin cancer	7.99e-05	0.00103	CcSEcCtD
Gemcitabine—Alanine aminotransferase increased—Docetaxel—skin cancer	7.96e-05	0.00103	CcSEcCtD
Gemcitabine—Oedema—Bleomycin—skin cancer	7.91e-05	0.00102	CcSEcCtD
Gemcitabine—Anaphylactic shock—Bleomycin—skin cancer	7.91e-05	0.00102	CcSEcCtD
Gemcitabine—Back pain—Temozolomide—skin cancer	7.91e-05	0.00102	CcSEcCtD
Gemcitabine—Pruritus—Imiquimod—skin cancer	7.88e-05	0.00102	CcSEcCtD
Gemcitabine—Infection—Bleomycin—skin cancer	7.86e-05	0.00101	CcSEcCtD
Gemcitabine—TYMS—Fluoropyrimidine Activity—TP53—skin cancer	7.77e-05	0.00184	CbGpPWpGaD
Gemcitabine—Nausea—Vemurafenib—skin cancer	7.75e-05	0.001	CcSEcCtD
Gemcitabine—Thrombocytopenia—Bleomycin—skin cancer	7.74e-05	0.000999	CcSEcCtD
Gemcitabine—Arrhythmia—Fluorouracil—skin cancer	7.73e-05	0.000997	CcSEcCtD
Gemcitabine—POLA1—E2F transcription factor network—CDKN2A—skin cancer	7.72e-05	0.00183	CbGpPWpGaD
Gemcitabine—Myalgia—Dactinomycin—skin cancer	7.7e-05	0.000993	CcSEcCtD
Gemcitabine—Bronchospasm—Docetaxel—skin cancer	7.67e-05	0.00099	CcSEcCtD
Gemcitabine—Alopecia—Fluorouracil—skin cancer	7.65e-05	0.000986	CcSEcCtD
Gemcitabine—CDA—Metabolism—PLIN2—skin cancer	7.64e-05	0.00181	CbGpPWpGaD
Gemcitabine—Diarrhoea—Imiquimod—skin cancer	7.62e-05	0.000983	CcSEcCtD
Gemcitabine—Discomfort—Dactinomycin—skin cancer	7.6e-05	0.000981	CcSEcCtD
Gemcitabine—Ill-defined disorder—Temozolomide—skin cancer	7.59e-05	0.000979	CcSEcCtD
Gemcitabine—Anaemia—Temozolomide—skin cancer	7.56e-05	0.000975	CcSEcCtD
Gemcitabine—Anorexia—Bleomycin—skin cancer	7.54e-05	0.000973	CcSEcCtD
Gemcitabine—Erythema—Fluorouracil—skin cancer	7.53e-05	0.000972	CcSEcCtD
Gemcitabine—Pancytopenia—Docetaxel—skin cancer	7.41e-05	0.000956	CcSEcCtD
Gemcitabine—TYMS—E2F transcription factor network—CDKN2A—skin cancer	7.4e-05	0.00175	CbGpPWpGaD
Gemcitabine—Hypotension—Bleomycin—skin cancer	7.39e-05	0.000953	CcSEcCtD
Gemcitabine—Oedema—Dactinomycin—skin cancer	7.38e-05	0.000952	CcSEcCtD
Gemcitabine—Malaise—Temozolomide—skin cancer	7.37e-05	0.000951	CcSEcCtD
Gemcitabine—Infection—Dactinomycin—skin cancer	7.33e-05	0.000945	CcSEcCtD
Gemcitabine—Leukopenia—Temozolomide—skin cancer	7.32e-05	0.000944	CcSEcCtD
Gemcitabine—Neutropenia—Docetaxel—skin cancer	7.3e-05	0.000941	CcSEcCtD
Gemcitabine—Thrombocytopenia—Dactinomycin—skin cancer	7.22e-05	0.000932	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Bleomycin—skin cancer	7.21e-05	0.00093	CcSEcCtD
Gemcitabine—Cough—Temozolomide—skin cancer	7.13e-05	0.00092	CcSEcCtD
Gemcitabine—ABCB1—lymphoid tissue—skin cancer	7.12e-05	0.00234	CbGeAlD
Gemcitabine—Paraesthesia—Bleomycin—skin cancer	7.1e-05	0.000916	CcSEcCtD
Gemcitabine—Vomiting—Imiquimod—skin cancer	7.08e-05	0.000913	CcSEcCtD
Gemcitabine—Hypertension—Temozolomide—skin cancer	7.06e-05	0.000911	CcSEcCtD
Gemcitabine—Dyspnoea—Bleomycin—skin cancer	7.05e-05	0.00091	CcSEcCtD
Gemcitabine—Anorexia—Dactinomycin—skin cancer	7.03e-05	0.000907	CcSEcCtD
Gemcitabine—Rash—Imiquimod—skin cancer	7.02e-05	0.000906	CcSEcCtD
Gemcitabine—Dermatitis—Imiquimod—skin cancer	7.01e-05	0.000905	CcSEcCtD
Gemcitabine—Pneumonia—Docetaxel—skin cancer	7e-05	0.000903	CcSEcCtD
Gemcitabine—Headache—Imiquimod—skin cancer	6.97e-05	0.0009	CcSEcCtD
Gemcitabine—Anaemia—Fluorouracil—skin cancer	6.96e-05	0.000898	CcSEcCtD
Gemcitabine—Myalgia—Temozolomide—skin cancer	6.96e-05	0.000898	CcSEcCtD
Gemcitabine—Arthralgia—Temozolomide—skin cancer	6.96e-05	0.000898	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	6.91e-05	0.000892	CcSEcCtD
Gemcitabine—RRM2—Mitotic G1-G1/S phases—CDKN2A—skin cancer	6.9e-05	0.00164	CbGpPWpGaD
Gemcitabine—Stevens-Johnson syndrome—Docetaxel—skin cancer	6.9e-05	0.00089	CcSEcCtD
Gemcitabine—Discomfort—Temozolomide—skin cancer	6.88e-05	0.000887	CcSEcCtD
Gemcitabine—Decreased appetite—Bleomycin—skin cancer	6.88e-05	0.000887	CcSEcCtD
Gemcitabine—ABCB1—female reproductive system—skin cancer	6.86e-05	0.00225	CbGeAlD
Gemcitabine—Acute coronary syndrome—Docetaxel—skin cancer	6.86e-05	0.000885	CcSEcCtD
Gemcitabine—Renal failure—Docetaxel—skin cancer	6.84e-05	0.000882	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Docetaxel—skin cancer	6.82e-05	0.00088	CcSEcCtD
Gemcitabine—Myocardial infarction—Docetaxel—skin cancer	6.82e-05	0.00088	CcSEcCtD
Gemcitabine—Stomatitis—Docetaxel—skin cancer	6.78e-05	0.000875	CcSEcCtD
Gemcitabine—CMPK1—Metabolism—ENO2—skin cancer	6.77e-05	0.0016	CbGpPWpGaD
Gemcitabine—Pain—Bleomycin—skin cancer	6.76e-05	0.000873	CcSEcCtD
Gemcitabine—Leukopenia—Fluorouracil—skin cancer	6.74e-05	0.00087	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Dactinomycin—skin cancer	6.72e-05	0.000867	CcSEcCtD
Gemcitabine—Anaphylactic shock—Temozolomide—skin cancer	6.67e-05	0.000861	CcSEcCtD
Gemcitabine—Oedema—Temozolomide—skin cancer	6.67e-05	0.000861	CcSEcCtD
Gemcitabine—POLA1—S Phase—CDK4—skin cancer	6.66e-05	0.00158	CbGpPWpGaD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	6.63e-05	0.00157	CbGpPWpGaD
Gemcitabine—Infection—Temozolomide—skin cancer	6.63e-05	0.000855	CcSEcCtD
Gemcitabine—POLE—Mitotic G1-G1/S phases—CDKN2A—skin cancer	6.63e-05	0.00157	CbGpPWpGaD
Gemcitabine—Nausea—Imiquimod—skin cancer	6.61e-05	0.000853	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Docetaxel—skin cancer	6.58e-05	0.000849	CcSEcCtD
Gemcitabine—Nervous system disorder—Temozolomide—skin cancer	6.54e-05	0.000844	CcSEcCtD
Gemcitabine—Thrombocytopenia—Temozolomide—skin cancer	6.53e-05	0.000843	CcSEcCtD
Gemcitabine—Feeling abnormal—Bleomycin—skin cancer	6.52e-05	0.000841	CcSEcCtD
Gemcitabine—Agranulocytosis—Docetaxel—skin cancer	6.49e-05	0.000838	CcSEcCtD
Gemcitabine—Skin disorder—Temozolomide—skin cancer	6.48e-05	0.000836	CcSEcCtD
Gemcitabine—Hyperhidrosis—Temozolomide—skin cancer	6.45e-05	0.000832	CcSEcCtD
Gemcitabine—Chest pain—Fluorouracil—skin cancer	6.41e-05	0.000827	CcSEcCtD
Gemcitabine—Myalgia—Fluorouracil—skin cancer	6.41e-05	0.000827	CcSEcCtD
Gemcitabine—Decreased appetite—Dactinomycin—skin cancer	6.41e-05	0.000827	CcSEcCtD
Gemcitabine—POLE—G1 to S cell cycle control—TP53—skin cancer	6.38e-05	0.00151	CbGpPWpGaD
Gemcitabine—Fatigue—Dactinomycin—skin cancer	6.36e-05	0.00082	CcSEcCtD
Gemcitabine—Anorexia—Temozolomide—skin cancer	6.36e-05	0.00082	CcSEcCtD
Gemcitabine—Discomfort—Fluorouracil—skin cancer	6.34e-05	0.000817	CcSEcCtD
Gemcitabine—Pain—Dactinomycin—skin cancer	6.31e-05	0.000814	CcSEcCtD
Gemcitabine—Haemoglobin—Docetaxel—skin cancer	6.28e-05	0.00081	CcSEcCtD
Gemcitabine—Rhinitis—Docetaxel—skin cancer	6.26e-05	0.000808	CcSEcCtD
Gemcitabine—Body temperature increased—Bleomycin—skin cancer	6.25e-05	0.000807	CcSEcCtD
Gemcitabine—Haemorrhage—Docetaxel—skin cancer	6.25e-05	0.000806	CcSEcCtD
Gemcitabine—Pharyngitis—Docetaxel—skin cancer	6.2e-05	0.0008	CcSEcCtD
Gemcitabine—POLA1—Mitotic G1-G1/S phases—CDK4—skin cancer	6.18e-05	0.00146	CbGpPWpGaD
Gemcitabine—Urinary tract disorder—Docetaxel—skin cancer	6.17e-05	0.000796	CcSEcCtD
Gemcitabine—CDA—Metabolism—CSPG4—skin cancer	6.16e-05	0.00146	CbGpPWpGaD
Gemcitabine—Oedema peripheral—Docetaxel—skin cancer	6.15e-05	0.000794	CcSEcCtD
Gemcitabine—Anaphylactic shock—Fluorouracil—skin cancer	6.15e-05	0.000793	CcSEcCtD
Gemcitabine—Oedema—Fluorouracil—skin cancer	6.15e-05	0.000793	CcSEcCtD
Gemcitabine—Connective tissue disorder—Docetaxel—skin cancer	6.14e-05	0.000792	CcSEcCtD
Gemcitabine—Urethral disorder—Docetaxel—skin cancer	6.12e-05	0.00079	CcSEcCtD
Gemcitabine—Infection—Fluorouracil—skin cancer	6.11e-05	0.000788	CcSEcCtD
Gemcitabine—Feeling abnormal—Dactinomycin—skin cancer	6.08e-05	0.000784	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Temozolomide—skin cancer	6.08e-05	0.000784	CcSEcCtD
Gemcitabine—Insomnia—Temozolomide—skin cancer	6.03e-05	0.000778	CcSEcCtD
Gemcitabine—Nervous system disorder—Fluorouracil—skin cancer	6.03e-05	0.000778	CcSEcCtD
Gemcitabine—Thrombocytopenia—Fluorouracil—skin cancer	6.02e-05	0.000776	CcSEcCtD
Gemcitabine—Paraesthesia—Temozolomide—skin cancer	5.99e-05	0.000773	CcSEcCtD
Gemcitabine—Dyspnoea—Temozolomide—skin cancer	5.95e-05	0.000767	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.94e-05	0.00141	CbGpPWpGaD
Gemcitabine—Somnolence—Temozolomide—skin cancer	5.93e-05	0.000765	CcSEcCtD
Gemcitabine—TYMS—Mitotic G1-G1/S phases—CDK4—skin cancer	5.92e-05	0.0014	CbGpPWpGaD
Gemcitabine—Erythema multiforme—Docetaxel—skin cancer	5.91e-05	0.000762	CcSEcCtD
Gemcitabine—Anorexia—Fluorouracil—skin cancer	5.86e-05	0.000756	CcSEcCtD
Gemcitabine—Body temperature increased—Dactinomycin—skin cancer	5.83e-05	0.000752	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle—MLH1—skin cancer	5.83e-05	0.00138	CbGpPWpGaD
Gemcitabine—Decreased appetite—Temozolomide—skin cancer	5.8e-05	0.000748	CcSEcCtD
Gemcitabine—Cardiac disorder—Docetaxel—skin cancer	5.8e-05	0.000748	CcSEcCtD
Gemcitabine—POLD1—Cell Cycle—MLH1—skin cancer	5.79e-05	0.00137	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—PLIN2—skin cancer	5.79e-05	0.00137	CbGpPWpGaD
Gemcitabine—Gastrointestinal disorder—Temozolomide—skin cancer	5.76e-05	0.000743	CcSEcCtD
Gemcitabine—Fatigue—Temozolomide—skin cancer	5.75e-05	0.000742	CcSEcCtD
Gemcitabine—Hypotension—Fluorouracil—skin cancer	5.74e-05	0.000741	CcSEcCtD
Gemcitabine—ABCB1—head—skin cancer	5.74e-05	0.00188	CbGeAlD
Gemcitabine—Constipation—Temozolomide—skin cancer	5.71e-05	0.000736	CcSEcCtD
Gemcitabine—Pain—Temozolomide—skin cancer	5.71e-05	0.000736	CcSEcCtD
Gemcitabine—Asthenia—Bleomycin—skin cancer	5.68e-05	0.000732	CcSEcCtD
Gemcitabine—Angiopathy—Docetaxel—skin cancer	5.67e-05	0.000731	CcSEcCtD
Gemcitabine—Immune system disorder—Docetaxel—skin cancer	5.64e-05	0.000728	CcSEcCtD
Gemcitabine—Mediastinal disorder—Docetaxel—skin cancer	5.63e-05	0.000726	CcSEcCtD
Gemcitabine—Chills—Docetaxel—skin cancer	5.6e-05	0.000723	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Fluorouracil—skin cancer	5.6e-05	0.000723	CcSEcCtD
Gemcitabine—Pruritus—Bleomycin—skin cancer	5.6e-05	0.000722	CcSEcCtD
Gemcitabine—POLE—Cell Cycle—MLH1—skin cancer	5.59e-05	0.00133	CbGpPWpGaD
Gemcitabine—Arrhythmia—Docetaxel—skin cancer	5.58e-05	0.00072	CcSEcCtD
Gemcitabine—Insomnia—Fluorouracil—skin cancer	5.56e-05	0.000717	CcSEcCtD
Gemcitabine—Paraesthesia—Fluorouracil—skin cancer	5.52e-05	0.000712	CcSEcCtD
Gemcitabine—Alopecia—Docetaxel—skin cancer	5.52e-05	0.000712	CcSEcCtD
Gemcitabine—Feeling abnormal—Temozolomide—skin cancer	5.5e-05	0.000709	CcSEcCtD
Gemcitabine—Dyspnoea—Fluorouracil—skin cancer	5.48e-05	0.000707	CcSEcCtD
Gemcitabine—Somnolence—Fluorouracil—skin cancer	5.47e-05	0.000705	CcSEcCtD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—TP53—skin cancer	5.46e-05	0.00129	CbGpPWpGaD
Gemcitabine—Erythema—Docetaxel—skin cancer	5.44e-05	0.000701	CcSEcCtD
Gemcitabine—Decreased appetite—Fluorouracil—skin cancer	5.34e-05	0.000689	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Fluorouracil—skin cancer	5.31e-05	0.000685	CcSEcCtD
Gemcitabine—Asthenia—Dactinomycin—skin cancer	5.29e-05	0.000683	CcSEcCtD
Gemcitabine—Body temperature increased—Temozolomide—skin cancer	5.27e-05	0.00068	CcSEcCtD
Gemcitabine—Back pain—Docetaxel—skin cancer	5.26e-05	0.000678	CcSEcCtD
Gemcitabine—Pain—Fluorouracil—skin cancer	5.26e-05	0.000678	CcSEcCtD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—TP53—skin cancer	5.24e-05	0.00124	CbGpPWpGaD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—skin cancer	5.1e-05	0.00121	CbGpPWpGaD
Gemcitabine—Feeling abnormal—Fluorouracil—skin cancer	5.07e-05	0.000654	CcSEcCtD
Gemcitabine—Diarrhoea—Dactinomycin—skin cancer	5.05e-05	0.000651	CcSEcCtD
Gemcitabine—Vomiting—Bleomycin—skin cancer	5.03e-05	0.000649	CcSEcCtD
Gemcitabine—Anaemia—Docetaxel—skin cancer	5.02e-05	0.000648	CcSEcCtD
Gemcitabine—Rash—Bleomycin—skin cancer	4.99e-05	0.000643	CcSEcCtD
Gemcitabine—Dermatitis—Bleomycin—skin cancer	4.98e-05	0.000643	CcSEcCtD
Gemcitabine—Leukopenia—Docetaxel—skin cancer	4.87e-05	0.000628	CcSEcCtD
Gemcitabine—Body temperature increased—Fluorouracil—skin cancer	4.86e-05	0.000627	CcSEcCtD
Gemcitabine—Asthenia—Temozolomide—skin cancer	4.79e-05	0.000618	CcSEcCtD
Gemcitabine—RRM2—Metabolism—PLIN2—skin cancer	4.77e-05	0.00113	CbGpPWpGaD
Gemcitabine—Cough—Docetaxel—skin cancer	4.74e-05	0.000612	CcSEcCtD
Gemcitabine—POLD1—Metabolism—PLIN2—skin cancer	4.74e-05	0.00112	CbGpPWpGaD
Gemcitabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—skin cancer	4.72e-05	0.00112	CbGpPWpGaD
Gemcitabine—Pruritus—Temozolomide—skin cancer	4.72e-05	0.000609	CcSEcCtD
Gemcitabine—Nausea—Bleomycin—skin cancer	4.7e-05	0.000606	CcSEcCtD
Gemcitabine—Hypertension—Docetaxel—skin cancer	4.69e-05	0.000606	CcSEcCtD
Gemcitabine—Vomiting—Dactinomycin—skin cancer	4.69e-05	0.000605	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.68e-05	0.00111	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—CSPG4—skin cancer	4.66e-05	0.00111	CbGpPWpGaD
Gemcitabine—Rash—Dactinomycin—skin cancer	4.65e-05	0.0006	CcSEcCtD
Gemcitabine—Arthralgia—Docetaxel—skin cancer	4.63e-05	0.000597	CcSEcCtD
Gemcitabine—Chest pain—Docetaxel—skin cancer	4.63e-05	0.000597	CcSEcCtD
Gemcitabine—Myalgia—Docetaxel—skin cancer	4.63e-05	0.000597	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	4.6e-05	0.000593	CcSEcCtD
Gemcitabine—Diarrhoea—Temozolomide—skin cancer	4.57e-05	0.000589	CcSEcCtD
Gemcitabine—TYMS—Mitotic G1-G1/S phases—CDKN2A—skin cancer	4.52e-05	0.00107	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.48e-05	0.00106	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—PLIN2—skin cancer	4.45e-05	0.00106	CbGpPWpGaD
Gemcitabine—Oedema—Docetaxel—skin cancer	4.44e-05	0.000572	CcSEcCtD
Gemcitabine—Anaphylactic shock—Docetaxel—skin cancer	4.44e-05	0.000572	CcSEcCtD
Gemcitabine—Infection—Docetaxel—skin cancer	4.41e-05	0.000569	CcSEcCtD
Gemcitabine—Nausea—Dactinomycin—skin cancer	4.38e-05	0.000565	CcSEcCtD
Gemcitabine—Nervous system disorder—Docetaxel—skin cancer	4.35e-05	0.000561	CcSEcCtD
Gemcitabine—Pruritus—Fluorouracil—skin cancer	4.35e-05	0.000561	CcSEcCtD
Gemcitabine—Thrombocytopenia—Docetaxel—skin cancer	4.34e-05	0.00056	CcSEcCtD
Gemcitabine—Skin disorder—Docetaxel—skin cancer	4.31e-05	0.000556	CcSEcCtD
Gemcitabine—TYMS—Circadian rythm related genes—CDK4—skin cancer	4.3e-05	0.00102	CbGpPWpGaD
Gemcitabine—Vomiting—Temozolomide—skin cancer	4.24e-05	0.000547	CcSEcCtD
Gemcitabine—Anorexia—Docetaxel—skin cancer	4.23e-05	0.000546	CcSEcCtD
Gemcitabine—Rash—Temozolomide—skin cancer	4.21e-05	0.000543	CcSEcCtD
Gemcitabine—Diarrhoea—Fluorouracil—skin cancer	4.21e-05	0.000543	CcSEcCtD
Gemcitabine—Dermatitis—Temozolomide—skin cancer	4.2e-05	0.000542	CcSEcCtD
Gemcitabine—CDA—Metabolism—ENO2—skin cancer	4.18e-05	0.000992	CbGpPWpGaD
Gemcitabine—Headache—Temozolomide—skin cancer	4.18e-05	0.000539	CcSEcCtD
Gemcitabine—Hypotension—Docetaxel—skin cancer	4.15e-05	0.000535	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Docetaxel—skin cancer	4.04e-05	0.000521	CcSEcCtD
Gemcitabine—ABCB1—lymph node—skin cancer	4.02e-05	0.00132	CbGeAlD
Gemcitabine—Insomnia—Docetaxel—skin cancer	4.01e-05	0.000518	CcSEcCtD
Gemcitabine—POLA1—Cell Cycle—MLH1—skin cancer	3.99e-05	0.000945	CbGpPWpGaD
Gemcitabine—Paraesthesia—Docetaxel—skin cancer	3.98e-05	0.000514	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.98e-05	0.000942	CbGpPWpGaD
Gemcitabine—Nausea—Temozolomide—skin cancer	3.96e-05	0.000511	CcSEcCtD
Gemcitabine—Dyspnoea—Docetaxel—skin cancer	3.96e-05	0.00051	CcSEcCtD
Gemcitabine—Somnolence—Docetaxel—skin cancer	3.94e-05	0.000509	CcSEcCtD
Gemcitabine—CMPK1—Metabolism—ERCC2—skin cancer	3.93e-05	0.000932	CbGpPWpGaD
Gemcitabine—Vomiting—Fluorouracil—skin cancer	3.91e-05	0.000504	CcSEcCtD
Gemcitabine—Rash—Fluorouracil—skin cancer	3.88e-05	0.0005	CcSEcCtD
Gemcitabine—Dermatitis—Fluorouracil—skin cancer	3.87e-05	0.0005	CcSEcCtD
Gemcitabine—Decreased appetite—Docetaxel—skin cancer	3.86e-05	0.000498	CcSEcCtD
Gemcitabine—Headache—Fluorouracil—skin cancer	3.85e-05	0.000497	CcSEcCtD
Gemcitabine—RRM2—Metabolism—CSPG4—skin cancer	3.84e-05	0.00091	CbGpPWpGaD
Gemcitabine—Gastrointestinal disorder—Docetaxel—skin cancer	3.83e-05	0.000494	CcSEcCtD
Gemcitabine—Fatigue—Docetaxel—skin cancer	3.83e-05	0.000493	CcSEcCtD
Gemcitabine—TYMS—Cell Cycle—MLH1—skin cancer	3.82e-05	0.000905	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—CSPG4—skin cancer	3.82e-05	0.000905	CbGpPWpGaD
Gemcitabine—Pain—Docetaxel—skin cancer	3.79e-05	0.000489	CcSEcCtD
Gemcitabine—Constipation—Docetaxel—skin cancer	3.79e-05	0.000489	CcSEcCtD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	3.73e-05	0.000885	CbGpPWpGaD
Gemcitabine—Feeling abnormal—Docetaxel—skin cancer	3.66e-05	0.000472	CcSEcCtD
Gemcitabine—Nausea—Fluorouracil—skin cancer	3.65e-05	0.000471	CcSEcCtD
Gemcitabine—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	3.62e-05	0.000857	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—CSPG4—skin cancer	3.59e-05	0.000851	CbGpPWpGaD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—skin cancer	3.58e-05	0.000848	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.53e-05	0.000838	CbGpPWpGaD
Gemcitabine—Body temperature increased—Docetaxel—skin cancer	3.51e-05	0.000452	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	3.35e-05	0.000793	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—CDK4—skin cancer	3.31e-05	0.000785	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—TERT—skin cancer	3.31e-05	0.000784	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—CDK4—skin cancer	3.29e-05	0.00078	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—TERT—skin cancer	3.29e-05	0.000779	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	3.2e-05	0.000759	CbGpPWpGaD
Gemcitabine—Asthenia—Docetaxel—skin cancer	3.18e-05	0.000411	CcSEcCtD
Gemcitabine—POLE—Cell Cycle, Mitotic—CDK4—skin cancer	3.18e-05	0.000754	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—TERT—skin cancer	3.18e-05	0.000753	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—ENO2—skin cancer	3.17e-05	0.000751	CbGpPWpGaD
Gemcitabine—Pruritus—Docetaxel—skin cancer	3.14e-05	0.000405	CcSEcCtD
Gemcitabine—TYMS—Metabolism—PLIN2—skin cancer	3.12e-05	0.00074	CbGpPWpGaD
Gemcitabine—Diarrhoea—Docetaxel—skin cancer	3.04e-05	0.000392	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle—CDK4—skin cancer	2.96e-05	0.000702	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—CDK4—skin cancer	2.94e-05	0.000698	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—CDK4—skin cancer	2.84e-05	0.000674	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.84e-05	0.000673	CbGpPWpGaD
Gemcitabine—Vomiting—Docetaxel—skin cancer	2.82e-05	0.000364	CcSEcCtD
Gemcitabine—Rash—Docetaxel—skin cancer	2.8e-05	0.000361	CcSEcCtD
Gemcitabine—Dermatitis—Docetaxel—skin cancer	2.8e-05	0.000361	CcSEcCtD
Gemcitabine—Headache—Docetaxel—skin cancer	2.78e-05	0.000359	CcSEcCtD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.69e-05	0.000638	CbGpPWpGaD
Gemcitabine—Nausea—Docetaxel—skin cancer	2.64e-05	0.00034	CcSEcCtD
Gemcitabine—RRM2—Metabolism—ENO2—skin cancer	2.61e-05	0.000619	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—ENO2—skin cancer	2.6e-05	0.000615	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.53e-05	0.0006	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—CSPG4—skin cancer	2.52e-05	0.000597	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.52e-05	0.000596	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—ENO2—skin cancer	2.44e-05	0.000578	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.43e-05	0.000576	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—ERCC2—skin cancer	2.43e-05	0.000576	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—PTGS2—skin cancer	2.36e-05	0.000559	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—CDK4—skin cancer	2.27e-05	0.000537	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—CDKN2A—skin cancer	2.26e-05	0.000537	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—TERT—skin cancer	2.26e-05	0.000536	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—CDKN2A—skin cancer	2.25e-05	0.000533	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.24e-05	0.000531	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—CDKN2A—skin cancer	2.17e-05	0.000515	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—CDK4—skin cancer	2.17e-05	0.000514	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—TERT—skin cancer	2.17e-05	0.000514	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.15e-05	0.000509	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—CDK4—skin cancer	2.03e-05	0.00048	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.99e-05	0.000472	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.95e-05	0.000462	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—CDK4—skin cancer	1.94e-05	0.00046	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.91e-05	0.000452	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—ERCC2—skin cancer	1.84e-05	0.000436	CbGpPWpGaD
Gemcitabine—TYMS—Circadian rythm related genes—TP53—skin cancer	1.83e-05	0.000434	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.73e-05	0.00041	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—ENO2—skin cancer	1.71e-05	0.000406	CbGpPWpGaD
Gemcitabine—TYMS—Circadian rythm related genes—IL6—skin cancer	1.68e-05	0.000397	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.66e-05	0.000393	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—CDKN2A—skin cancer	1.55e-05	0.000367	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—ERCC2—skin cancer	1.52e-05	0.000359	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—ERCC2—skin cancer	1.51e-05	0.000357	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—CDKN2A—skin cancer	1.48e-05	0.000352	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—PTGS2—skin cancer	1.46e-05	0.000345	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—ERCC2—skin cancer	1.42e-05	0.000336	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.38e-05	0.000328	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—TP53—skin cancer	1.26e-05	0.000299	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—TP53—skin cancer	1.25e-05	0.000297	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—TP53—skin cancer	1.21e-05	0.000287	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—PTGS2—skin cancer	1.1e-05	0.000262	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—ERCC2—skin cancer	9.94e-06	0.000236	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	9.89e-06	0.000234	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—PLIN2—skin cancer	9.64e-06	0.000228	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—PTGS2—skin cancer	9.09e-06	0.000216	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—PTGS2—skin cancer	9.04e-06	0.000214	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—TP53—skin cancer	8.62e-06	0.000204	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—PTGS2—skin cancer	8.5e-06	0.000201	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—TP53—skin cancer	8.26e-06	0.000196	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—CSPG4—skin cancer	7.77e-06	0.000184	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.62e-06	0.000157	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—PTGS2—skin cancer	5.96e-06	0.000141	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.89e-06	0.000139	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—ENO2—skin cancer	5.28e-06	0.000125	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—ERCC2—skin cancer	3.07e-06	7.27e-05	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—PTGS2—skin cancer	1.84e-06	4.36e-05	CbGpPWpGaD
